Skip to main content

Treatment Clinical Trials for Chronic Lymphocytic Leukemia (CLL)

Review the chronic lymphocytic leukemia (cll) treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 108

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Zanubrutinib in Combination with Odronextamab for the Treatment of Patients with Richter’s Transformation
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Genetically Engineered Cells (Anti-CD19 CAR-T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies, The PRODIGY Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Genetically Engineered Cells (LMY-920) for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
TCRαβ+ and CD19+ Depleted Donor Lymphocyte Infusion after Donor Stem Cell Transplant for the Prevention of Relapse in Patients with High-Risk Blood Cancers
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells with Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Patients with Relapsed or Refractory B-cell Hematologic Malignancies
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
huCART19-IL18 Cells for the Treatment of Relapsed or Refractory CD19+ Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Acute Lymphoblastic Leukemia
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
T Lymphocytes Expressing the Kappa Chimeric Antigen Receptor (CAR) and CD28 Endodomain for the Treatment of Relapsed or Refractory B cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
CD19-CD34t Metabolically Programmed CAR T-Cell Therapy for the Treatment of Patients with CD19 Positive Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Status: Active
Location: See ClinicalTrials.gov
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Status: Active
Location: 3 locations
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.
Status: Active
Location: See ClinicalTrials.gov
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Status: Active
Location: See ClinicalTrials.gov
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Status: Active
Location: See ClinicalTrials.gov
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Status: Active
Location: See ClinicalTrials.gov
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
Status: Active
Location: See ClinicalTrials.gov
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Status: Active
Location: See ClinicalTrials.gov
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
Status: Active
Location: See ClinicalTrials.gov
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Status: Active
Location: See ClinicalTrials.gov
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Status: Active
Location: See ClinicalTrials.gov